Acorah Software Products - Accounts Production 16.1.300 false true 31 October 2023 1 November 2022 false 1 November 2023 31 October 2024 31 October 2024 09803003 Mr Paul McConnell Mrs Edwina McMillan Mr Ian Moore Mr Samantha Ormrod Mr Shaun Fahy Mr Paul McConnell iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 09803003 2023-10-31 09803003 2024-10-31 09803003 2023-11-01 2024-10-31 09803003 frs-core:CurrentFinancialInstruments 2024-10-31 09803003 frs-core:Non-currentFinancialInstruments 2024-10-31 09803003 frs-core:FurnitureFittings 2024-10-31 09803003 frs-core:FurnitureFittings 2023-11-01 2024-10-31 09803003 frs-core:FurnitureFittings 2023-10-31 09803003 frs-core:LandBuildings frs-core:LeasedAssetsHeldAsLessee 2024-10-31 09803003 frs-core:LandBuildings frs-core:LeasedAssetsHeldAsLessee 2023-11-01 2024-10-31 09803003 frs-core:LandBuildings frs-core:LeasedAssetsHeldAsLessee 2023-10-31 09803003 frs-core:PlantMachinery 2024-10-31 09803003 frs-core:PlantMachinery 2023-11-01 2024-10-31 09803003 frs-core:PlantMachinery 2023-10-31 09803003 frs-core:RevaluationReserve 2023-10-31 09803003 frs-core:RevaluationReserve 2024-10-31 09803003 frs-core:ShareCapital 2024-10-31 09803003 frs-core:RetainedEarningsAccumulatedLosses 2024-10-31 09803003 frs-bus:PrivateLimitedCompanyLtd 2023-11-01 2024-10-31 09803003 frs-bus:FilletedAccounts 2023-11-01 2024-10-31 09803003 frs-bus:SmallEntities 2023-11-01 2024-10-31 09803003 frs-bus:AuditExempt-NoAccountantsReport 2023-11-01 2024-10-31 09803003 frs-bus:SmallCompaniesRegimeForAccounts 2023-11-01 2024-10-31 09803003 frs-bus:Director1 2023-11-01 2024-10-31 09803003 frs-bus:Director2 2023-11-01 2024-10-31 09803003 frs-bus:Director3 2023-11-01 2024-10-31 09803003 frs-bus:Director4 2023-11-01 2024-10-31 09803003 frs-bus:Director5 2023-11-01 2024-10-31 09803003 frs-bus:CompanySecretary1 2023-11-01 2024-10-31 09803003 frs-countries:EnglandWales 2023-11-01 2024-10-31 09803003 2022-10-31 09803003 2023-10-31 09803003 2022-11-01 2023-10-31 09803003 frs-core:CurrentFinancialInstruments 2023-10-31 09803003 frs-core:Non-currentFinancialInstruments 2023-10-31 09803003 frs-core:RevaluationReserve 2023-10-31 09803003 frs-core:ShareCapital 2023-10-31 09803003 frs-core:RetainedEarningsAccumulatedLosses 2023-10-31
Registered number: 09803003
Apollo Pharma Ltd
Unaudited Financial Statements
For The Year Ended 31 October 2024
The Accountants
Contents
Page
Balance Sheet 1—2
Notes to the Financial Statements 3—4
Page 1
Balance Sheet
Registered number: 09803003
2024 2023
Notes £ £ £ £
FIXED ASSETS
Tangible Assets 4 119,176 150,078
119,176 150,078
CURRENT ASSETS
Stocks 5 376,422 170,666
Debtors 6 156,987 305,737
Cash at bank and in hand 17,998 22,999
551,407 499,402
Creditors: Amounts Falling Due Within One Year 7 (361,233 ) (562,738 )
NET CURRENT ASSETS (LIABILITIES) 190,174 (63,336 )
TOTAL ASSETS LESS CURRENT LIABILITIES 309,350 86,742
Creditors: Amounts Falling Due After More Than One Year 8 (164,414 ) (169,018 )
NET ASSETS/(LIABILITIES) 144,936 (82,276 )
CAPITAL AND RESERVES
Called up share capital 9 332,000 332,000
Revaluation reserve 10 157,830 157,830
Profit and Loss Account (344,894 ) (572,106 )
SHAREHOLDERS' FUNDS 144,936 (82,276)
Page 1
Page 2
For the year ending 31 October 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Mr Paul McConnell
Director
20/12/2024
The notes on pages 3 to 4 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. General Information
Apollo Pharma Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 09803003 . The registered office is Unit 1 Irwell Works, Lower Woodhill Rd, Bury, BL9 1AA.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.
Sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.
Rendering of services
Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
2.3. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:
Leasehold 11% SL
Plant & Machinery 15% RB and 33% RB
Fixtures & Fittings 33% RB
2.4. Stocks and Work in Progress
Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 20 (2023: 22)
20 22
4. Tangible Assets
Land & Property
Leasehold Plant & Machinery Fixtures & Fittings Total
£ £ £ £
Cost
As at 1 November 2023 242,653 312,854 4,460 559,967
Additions - 20,595 - 20,595
As at 31 October 2024 242,653 333,449 4,460 580,562
...CONTINUED
Page 3
Page 4
Depreciation
As at 1 November 2023 161,769 244,839 3,281 409,889
Provided during the period 26,961 24,147 389 51,497
As at 31 October 2024 188,730 268,986 3,670 461,386
Net Book Value
As at 31 October 2024 53,923 64,463 790 119,176
As at 1 November 2023 80,884 68,015 1,179 150,078
5. Stocks
2024 2023
£ £
Stock 376,422 170,666
6. Debtors
2024 2023
£ £
Due within one year
Trade debtors 101,987 250,737
Other debtors 55,000 55,000
156,987 305,737
7. Creditors: Amounts Falling Due Within One Year
2024 2023
£ £
Trade creditors 86,270 264,711
Bank loans and overdrafts 10,000 10,000
Other creditors 122,185 120,990
Taxation and social security 142,778 167,037
361,233 562,738
8. Creditors: Amounts Falling Due After More Than One Year
2024 2023
£ £
Bank loans 164,414 169,018
9. Share Capital
2024 2023
£ £
Allotted, Called up and fully paid 332,000 332,000
10. Reserves
Revaluation Reserve
£
As at 1 November 2023 157,830
As at 31 October 2024 157,830
Page 4